Cerebral — the ridiculously, predictably profitable, telehealth startup somehow allowed to sell stimulants, benzodiazepines, and even Suboxone often after just 30 minutes of online “consultation” — is continuing its policy walk-back in the wake of damning reports that the company was, well, somehow allowed to sell stimulants, benzodiazepines, and even Suboxone after just 30 minutes of online “consultation.”
According to a new report from The Wall Street Journal, CEO and co-founder, Kyle Robertson, emailed his employees on Monday to announce that Cerebral would cease prescribing all controlled substances “excluding those in one category” to new patients beginning this Friday, with plans to taper existing patients off by October while also working to transfer them to in-person clinicians. Instead of copping to his unethical, and effective plan to peddle drugs via social media, Robertson justified the strategic retreat by pinning it all on “the evolving landscape around the accessibility of mental-health care, and the ability for patients to return to an in-person or hybrid care model for this treatment.”
